Protalix BioTherapeutics ...

2.56
-0.05 (-1.92%)
At close: Apr 21, 2025, 3:59 PM
2.57
0.55%
Pre-market: Apr 22, 2025, 04:01 AM EDT
-1.92%
Bid 2.55
Market Cap 199.37M
Revenue (ttm) 53.4M
Net Income (ttm) 2.93M
EPS (ttm) 0.04
PE Ratio (ttm) 63.88
Forward PE 3.11
Analyst Strong Buy
Ask 3
Volume 277,918
Avg. Volume (20D) 686,195
Open 2.29
Previous Close 2.61
Day's Range 2.50 - 2.61
52-Week Range 0.82 - 2.76
Beta 0.46

About PLX

Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease. Its product pipeline comprises PRX-102, a therapeutic protein candi...

Industry Biotechnology
Sector Healthcare
IPO Date May 15, 1998
Employees 213
Stock Exchange AMEX
Ticker Symbol PLX
Full Company Profile

Analyst Forecast

According to 1 analyst ratings, the average rating for PLX stock is "Strong Buy." The 12-month stock price forecast is $15, which is an increase of 487.08% from the latest price.

Stock Forecasts

Next Earnings Release

Protalix BioTherapeutics Inc. is scheduled to release its earnings on May 9, 2025, before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
1 month ago
+9.38%
Protalix BioTherapeutics shares are trading higher... Unlock content with Pro Subscription
8 months ago
-10.58%
Protalix BioTherapeutics shares are trading lower after the company reported worse-than-expected Q2 EPS results.